Header image

ADVANCES IN NEURODEGENERATIVE DISEASES: FROM NOVEL THERAPIES TO REAL-WORLD CLINICAL VALIDATION

Tracks
SPEAKER'S ROOM 1: DOROTEA BARNÉS
Wednesday, September 30, 2026
16:00 - 16:45
SPEAKERS' CORNER 1: DOROTEA BARNÉS

Overview

Sponsor: Euskadi


Details

Neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Alzheimer's Disease continue to pose major scientific, clinical, and societal challenges. At the same time, unprecedented advances in molecular biology, drug discovery, biomarkers, precision medicine, and advanced therapeutic approaches are transforming the landscape of neurological research and care. This round table will bring together leading experts from academia, biotechnology, and clinical practice to discuss the latest innovations driving the development of next-generation therapies for neurodegenerative disorders. The discussion will explore emerging therapeutic strategies, including novel small molecules, biologics, regenerative and gene-based approaches, as well as the critical role of translational research in accelerating their path to patients. Participants will examine how cutting-edge discoveries are being validated through clinical studies and real-world evidence, addressing key challenges related to efficacy assessment, biomarker development, patient stratification, regulatory pathways, and long-term outcomes. Particular attention will be given to lessons learned across ALS, MS, and Alzheimer's disease, highlighting opportunities for cross-disciplinary collaboration and innovation. Featuring insights from Adolfo López de Munain, representatives of Golden Gait Biotech and CIC bioGUNE, and Ana Martínez Gil, the session will provide a comprehensive perspective on how scientific breakthroughs are advancing from the laboratory to clinical validation and, ultimately, to improved patient outcomes.


Details

Maite Solas
Vice-president
FUNDELA

Moderator

Agenda Item Image
Manuel Cuervas-Mons Cantón
Medical Lead Innovative Medicines
Bristol Myers Squibb

.

Agenda Item Image
Yosu Vara
Chemistry and Manufacturing Director
Quimatriyx

.

Adolfo José Lopez de Munain
Miramoon Pharma & SEED-ALS coordinator/leader
Osakidetza, IIS Biogipuzkoa, Miramoon Pharma

.

Agenda Item Image
Ana Martinez Gil
Profesor de Investigación CSIC
CIB-CSIC

.

loading